An Early Phase 1 interventional study of Deep Brain Stimulation in Parkinson Disease (PD), sponsored by University of Minnesota. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by University of Minnesota · Early Phase 1, Interventional, and Basic science
Among 33 studies in Parkinson Disease by University of Minnesota — 17 open to participants now, 18 under way, none of them phase 3. Parkinson Disease · University of Minnesota.
Among the 33 studies in Parkinson Disease by University of Minnesota, this one is the 15th largest by planned enrollment of the 21 interventional ones that give a count, is one of 4 that started in 2026, is one of 6 in phase 1, reaches primary completion later than 17 of the 17 other live ones, and was the 33rd registered.
4,573 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →17 of the 33 studies in Parkinson Disease by University of Minnesota are open now, in 1 country. Recruiting first, the newest first:
University of Minnesota · Sites in United States
University of Minnesota · Sites in United States
University of Minnesota · Sites in United States
University of Minnesota · Sites in United States
University of Minnesota · Sites in United States
By country, each count listing its studies:
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 63 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 2 · Phase 3 1
First in 1999; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 15 is below the median of 40 across 3,353 interventional studies indexed under Parkinson Disease.
Median enrollment 24 across the 21 interventional studies, 49 across the 12 observational. Of the 14 that completed or were terminated, 2 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Minnesota is the lead sponsor of 1,216 studies on the registry; 197 are open to participants now.
Of its 136 completed or terminated interventional studies of FDA-regulated products, 95 (70%) have results posted.
10 of the studies in Parkinson Disease by University of Minnesota that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06692920University of MinnesotaCharacterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson's Disease. | 2026-12-01 |
| NCT05557864University of MinnesotaEffects of Pallidal Deep Brain Stimulation Location on Motor Impairment in Parkinson's Disease | 2026-12-31 |
| NCT05568199University of MinnesotaUdall Project 1 Aim 4 | 2027-03-01 |
| NCT05656586University of MinnesotaUdall Project 2 Aim 2A&C | 2027-03-01 |
| NCT05658302University of MinnesotaCircuit-Based Deep Brain Stimulation for Parkinson's Disease P1A2&3 Catalyst | 2027-03-01 |
Among the 33 studies in Parkinson Disease by University of Minnesota, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project aims to establish the feasibility of Bayesian optimization for tuning deep brain stimulation (DBS) to treat gait symptoms in Parkinson's disease (PD) patients. Our primary question is: Can Bayesian optimization of DBS achieve reproducible results within a feasible number of gait measurements? PD patients will be enrolled who have DBS of the subthalamic nucleus (STN) or globus pallidus (GP) in whom at least 3 months have passed since activation of their neurostimulators, for stabilization of clinical stimulator settings. We will apply Bayesian optimization to derive DBS settings which maximally lengthen step length relative to the OFF DBS state.
Patients will undergo on-label DBS for the treatment of Parkinson's disease, at stimulator settings different from their usual settings, but within the FDA-approved range for this indication, based on the output of the Bayesian optimization algorithm. Test settings will be evaluated by a brief period of walking on a treadmill which captures measurements of step length. The resulting step length will be provided to the algorithm to inform the next recommended test setting. This will be repeated approximately 30 times to reach putatively optimal DBS settings.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All participants will be allocated to this group for DBS stimulation within FDA-approved limits and labeling for symptoms of PD.
Other: Deep Brain Stimulation
DBS within FDA-approved limits and labeling for symptoms of PD
Gait Test
Subjects walk for one minute each on a treadmill set to match their individual overground walking speed. A forceplate measures the center of pressure trajectory from which integral software detects time and location of heel-strike and toe-off events. These events, and the treadmill speed, are used to compute step lengths.
Time frame: This will be repeated approximately 30 times throughout the study visit (Day 1) on various DBS settings to reach putatively optimal DBS settings.
Start is estimated for Dec 2026; primary completion for Mar 2031, 51 months later.
Of 77 non-industry phase 1 interventional studies under Parkinson Disease, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 68. This study's planned 51 months is above that.
Counting every sponsor, half of 204 studies reached it within 19 months; a quarter within 5 and three quarters within 40.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Sep 28, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.